Pediatric tumors are uncommon, yet are the leading cause of cancer-related death in
childhood. Tumor types, molecular characteristics, and pathogenesis are unique, often …

Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive, invasive cancer that
comprise around 10% of all soft tissue sarcomas and develop in about 8–13% of patients …

Learning Objectives Explain the characteristics and treatment of malignant peripheral nerve
sheath tumors, both in relation to neurofibromatosis type I and otherwise. Cite the unique …

Purpose To improve the risk stratification of patients with rhabdomyosarcoma (RMS) through
the use of clinical and molecular biologic data. Patients and Methods Two independent data …

There are conflicting reports as to whether malignant peripheral nerve sheath tumor
(MPNST) patients with neurofibromatosis type 1 (NF1) have worse prognosis than non-NF1 …

Abstract In the US, approximately 850–900 children are diagnosed each year with soft tissue
sarcomas (STS). Key findings from recent Children's Oncology Group (COG) clinical trials …

This paper describes the standard of care for patients with non-rhabdomyosarcoma soft
tissue sarcomas (NRSTS) and the therapeutic recommendations developed by the …

The paper report the results of the first European prospective nonrandomized trial dedicated
to pediatric synovial sarcoma. The study included 138 patients treated from 2005 to 2012 …

One of the most common malignancies affecting adults with the neurofibromatosis type 1
(NF1) cancer predisposition syndrome is the malignant peripheral nerve sheath tumor …

Malignant peripheral nerve sheath tumor (MPNST) is the leading cause of mortality in
patients with neurofibromatosis type 1. In 2002, an MPNST consensus statement reviewed …